Axsome Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Axsome Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-1.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-1.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: AXSM * şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: AXSM * şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Axsome Therapeutics Piyasaya Karşı Temettü Getirisi

AXSM * temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (AXSM *)	n/a
Pazarın Alt %25'i (MX)	2.7%
Pazarın En İyi %25'i (MX)	7.2%
Sektör Ortalaması (Pharmaceuticals)	2.3%
Analist tahmini (AXSM *) (3 yıla kadar)	0%

Önemli Temettü: AXSM * şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, AXSM * şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: AXSM * şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: AXSM * herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Axsome Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc

Second quarter 2024 earnings released: US$1.67 loss per share (vs US$1.54 loss in 2Q 2023)

Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Insufficient new directors

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Insufficient new directors

Forecast to breakeven in 2025

Insufficient new directors

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Insufficient new directors

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insufficient new directors

Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration

The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 12, 2022

Axsome Therapeutics Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs-05 on Anhedonia in Patients with Major Depressive Disorder

Axsome Therapeutics, Inc. Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs 05 on Anhedonia in Patients with Major Depressive Disorder

Axsome Therapeutics Announces Positive Results of the Evolve Trial of AXS-05 in Major Depressive Disorder

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in the Journal of Clinical Psychiatry

Axsome Therapeutics Announces Publication of Pivotal Ascend Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry

Insufficient new directors

Pomerantz Law Firm Announces the Filing of A Class Action Against Axsome Therapeutics, Inc. and Certain Officers

No longer forecast to breakeven

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q1, 2022 Results on May 02, 2022

Axsome Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million.

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Axsome and Baudax Bio, Inc. Enters into Litigation Discontinuance Agreement

Insufficient new directors

Insufficient new directors

Insufficient new directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin